Divi's Laboratories jumped 4.31% to Rs 5,864.55 after the pharma major's consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.
Total income grew by 23.13% year on year (YoY) to Rs 2,401 crore in the quarter ended 31 December 2024.
Profit before tax for the quarter was at Rs 726 crore, up 48.47% from Rs 489 crore reported in the same period a year ago.
Total expenses stood at Rs 1,675 crore in the third quarter of FY25, up 14.65% on YoY basis. Cost of material consumed was at Rs 1,021 crore (up 28.59% YoY) and employee benefit expenses stood at Rs 297 crore (up 10.82% YoY) during the period under review.
Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 18 crore posted in Q3 FY24.
Also Read
 "Stock Market, BSE, NSE, Nifty, Capital, Market")
 "Sandeep Dikshit, Congress leader")
 "Finance Minister Nirmala Sitharaman")
 "Vivo V40")
 "Kejriwal, Arvind Kejriwal")
On nine-month basis, the companys net profit climbed 43.97% to Rs 1,529 crore on 22.25% rise in revenue from operations to Rs 6,775 crore in 9M FY25 over 9M FY24.
Forex gain for the nine-month period amounted to Rs 38 crore as against a gain of Rs 32 crore posted in same period a year ago.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
